SkyView Investment Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

SkyView Investment Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-91	Closed	-$3K	–	603
2021 Q4	$3K	Buy	+91	New	+$2.86K	﹤0.01%	553
2021 Q3	–	Sell	-271	Closed	-$12K	–	396
2021 Q2	$12K	Hold	271	–	–	0.01%	257
2021 Q1	$12K	Buy	271 +226	+502%	+$12.6K	0.01%	265
2020 Q4	$3K	Buy	+45	New	+$2.24K	﹤0.01%	260

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

SkyView Investment Advisors's IONS Position: Q1 2022 in Review

SkyView Investment Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2022, closing a stake of 91 shares — an estimated $3K sold.

SkyView Investment Advisors first reported a position in IONS in Q4 2020 and held it in 4 quarters. The position peaked at $12K in Q2 2021. 332 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

SkyView Investment Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SkyView Investment Advisors sold 91 Ionis Pharmaceuticals shares in Q1 2022, an estimated $3K.
SkyView Investment Advisors first reported a position in Ionis Pharmaceuticals in Q4 2020 and held it in 4 quarters.
SkyView Investment Advisors's Ionis Pharmaceuticals position peaked at $12K in Q2 2021.
332 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on SkyView Investment Advisors's 13F filing for Q1 2022, filed 17 May 2022.